4-(3-甲基亚丁基)环己酮 | 250234-86-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-(3-甲基亚丁基)环己酮
• 英文名称: 4-(3-methylbutylidene)cyclohexanone
• 英文别名: 4-(3-methylbutylidene)-1-cyclohexanone；4-(3-methylbutylidene)cyclohexan-1-one
• CAS: 250234-86-7
• 化学式: C₁₁H₁₈O
• mdl: MFCD09031450
• 分子量: 166.263
• InChiKey: CXZGOWXDTMHMRA-UHFFFAOYSA-N

物化性质

• 沸点：
  248.8±9.0 °C(Predicted)
• 密度：
  0.977±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.727
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-(3-甲基亚丁基)环己酮 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 12.0h， 生成
  参考文献：
  名称：

  Discovery of Nonpeptidic Small-Molecule AP-1 Inhibitors:  Lead Hopping Based on a Three-Dimensional Pharmacophore Model

  摘要：

  We designed and synthesized small-molecule activator protein-1 (AP-1) inhibitors based on a three-dimensional (3D) pharmacophore model that we had previously derived from a cyclic decapeptide exhibiting AP-1 inhibitory activity. New AP-1 inhibitors with a 1-thia-4-azaspiro[4.5]decane or a benzophenone scaffold, which inhibit the DNA-binding and transactivation activities of AP-1, were discovered using a "lead hopping" procedure. An additional investigation of the benzophenone analogues confirmed the reliability of the pharmacophore model, its utility to discover AP-1 inhibitors, and the potency of the benzophenone derivatives as a lead series.

  DOI：

  10.1021/jm050550d
• 作为产物：
  描述：

  8-(3-methylbutylidene)-1,4-dioxaspiro[4.5]decane 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 9.0h， 生成 4-(3-甲基亚丁基)环己酮
  参考文献：
  名称：

  Discovery of Nonpeptidic Small-Molecule AP-1 Inhibitors:  Lead Hopping Based on a Three-Dimensional Pharmacophore Model

  摘要：

  We designed and synthesized small-molecule activator protein-1 (AP-1) inhibitors based on a three-dimensional (3D) pharmacophore model that we had previously derived from a cyclic decapeptide exhibiting AP-1 inhibitory activity. New AP-1 inhibitors with a 1-thia-4-azaspiro[4.5]decane or a benzophenone scaffold, which inhibit the DNA-binding and transactivation activities of AP-1, were discovered using a "lead hopping" procedure. An additional investigation of the benzophenone analogues confirmed the reliability of the pharmacophore model, its utility to discover AP-1 inhibitors, and the potency of the benzophenone derivatives as a lead series.

  DOI：

  10.1021/jm050550d

文献信息

• Spiro compounds or salts thereof and preventives/remedies for autoimmune diseases and AP-1 inhibitors containing the same
  申请人：Toyama Chemical Co., Ltd.

  公开号：US06384065B1

  公开（公告）日：2002-05-07

  The spiro compounds of the present invention represented by the general formula: wherein A, R2, R3, R4, R5, R6 and n are as defined in the specification, exhibit an AP-1 activity inhibitory action and, based on the AP-1 inhibitory action, suppresses the expression of a wide variety of genes and are useful as an agent for treating and preventing autoimmune diseases with lessoned side reactions.

  本发明的螺环化合物由以下一般式表示：其中A、R2、R3、R4、R5、R6和n如规范中所定义，表现出AP-1活性抑制作用，并基于AP-1抑制作用，抑制各种基因的表达，可用作治疗和预防自身免疫疾病并减少副作用的药剂。
• Compounds and medicinal use thereof
  申请人：Toyama Chemical Co., Ltd.

  公开号：US07314888B1

  公开（公告）日：2008-01-01

  A compound or a salt thereof having the atom corresponding to N3 and the two or more atoms selected from N1, N2, N4 and N5, said atoms constitute the pharmacophore represented by the following formula: and inhibits the activity of transcription factor AP-1 and is useful as an agent for preventing and treating the diseases into which over expression of AP-1 participates and as an AP-1 inhibitor.

  具有对应于N3的原子和由N1、N2、N4和N5中选择的两个或更多个原子构成的药效团的化合物或其盐，所述原子构成以下公式所代表的药效团，并抑制转录因子AP-1的活性，用作预防和治疗过度表达AP-1参与的疾病的药物和AP-1抑制剂。
• NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF
  申请人：Chaki Hisaaki

  公开号：US20090118169A1

  公开（公告）日：2009-05-07

  A compound comprising the atom corresponding to N 3 and the two or more atoms selected from N 1 , N 2 , N 4 and N 5 , said atoms constitute the pharmacophore represented by the following formula: wherein N 1 represents an atom to which a donative hydrogen atom in a hydrogen-bond donating group is bonded or a hydrogen-bond accepting atom in a hydrogen-bond accepting group; N 3 represents a hydrogen-bond accepting atom in a hydrogen-bond accepting group; and N 2 , N 4 and N 5 independently represents an arbitrary carbon atom constituting a hydrophobic group and defined by the interatomic distances between N 1 , N 2 , N 3 , N 4 and N 5 ; and, in the optimized three-dimensional structure thereof, the distances between the atom corresponding to N 3 and the two or more atoms selected from N 1 , N 2 , N 4 and N 5 , in the optimized steric structure thereof, are the interatomic distances in a pharmacophore; or a salt thereof; inhibits the activity of transcription factor AP-1 and is useful as an agent for preventing and treating the diseases into which overexpression of AP-1 participates and as an AP-1 inhibitor.

  该化合物由与N3对应的原子和从N1、N2、N4和N5中选择的两个或更多原子组成，这些原子构成了以下公式所代表的药效团：其中，N1代表氢键供体基团中的给氢原子所结合的原子或氢键受体基团中的接受氢原子的原子；N3代表氢键受体基团中的接受氢原子的原子；N2、N4和N5分别独立地表示构成疏水基团的任意碳原子，并由N1、N2、N3、N4和N5之间的原子间距离定义；在其优化的三维结构中，N3对应的原子与从N1、N2、N4和N5中选择的两个或更多原子之间的距离，在其优化的立体结构中，是药效团中的原子间距离；或其盐；抑制转录因子AP-1的活性，并且作为预防和治疗过度表达AP-1参与的疾病和AP-1抑制剂的制剂是有用的。
• Aldehydic ketones and their use in perfumes
  申请人：QUEST INTERNATIONAL B.V.

  公开号：EP0967195A1

  公开（公告）日：1999-12-29

  The novel ketones having the structure in which R is H or an alkyl group and X is a hydrocarbon group having between 4 and 12 carbon atoms, the ring being saturated or unsaturated, excluding 4-(1-ethylpropylidene)-1-cyclohexanone, 4-cyclohexylidene- 1-cyclohexanone,4-butylidene-1-cyclohex-2-enone, 4-(1-ethylpropylidene)-1-cyclohex-2-enone, 4-(2-methylpropylidene)-1-cyclohexanone,4-cyclohexyliden-2-cyclohexen-1-one, 4-(1,5-dimethyl-4-hexenylidene)-1-cyclohexanone, 4-[4-(cyclohexyliden)cyclohexyliden]-1-cyclohexanone, 4-[4-(tert-butyl)cyclohexyliden]-1-cyclohexanone, 4-[4-(cyclohexyl)cyclohexyliden]-1-cyclohexanone, 4-(2-isopropyl-5-methylcyclohexyliden)-2-cyclohexen-1-one and 4-(3-phenylpropylidene)-1-cyclohex-2-enone exhibit interesting odour characteristics, generally aldehydic in nature, and so find use in perfumes and in perfumed products.

  具有以下结构的新型酮 其中R为H或烷基，X为具有4至12个碳原子的烃基，环为饱和或不饱和环，不包括4-(1-乙基亚丙基)-1-环己酮，4-环己亚基-1-环己酮4-(1-乙基亚丙基)-1-环己-2-烯酮、4-(2-甲基亚丙基)-1-环己酮、4-环己亚基-2-环己烯-1-酮、4-(1,5-二甲基-4-亚己烯)-1-环己酮、4-[4-(环己亚基)环己亚基]-1-环己酮，4-[4-(叔丁基)环己亚基]-1-环己酮，4-[4-(环己基)环己亚基]-1-环己酮、4-(2-异丙基-5-甲基环己亚基)-2-环己烯-1-酮和 4-(3-苯基亚丙基)-1-环己-2-烯酮具有有趣的气味特征，一般为醛类，因此可用于香水和香料产品中。
• NOVEL SPIRO COMPOUNDS OR SALTS THEREOF AND PREVENTIVES/REMEDIES FOR AUTOIMMUNE DISEASES AND AP-1 INHIBITORS CONTAINING THE SAME
  申请人：TOYAMA CHEMICAL CO., LTD.

  公开号：EP1076056A1

  公开（公告）日：2001-02-14

  The spiro compounds of the present invention represented by the following general formula: wherein A, R2, R3, R4, R5, R6 and n are as defined in the specification, exhibit an AP-1 activity inhibitory action and, based on the AP-1 inhibitory action, suppresses the expression of a wide variety of genes and are useful as an agent for treating and preventing autoimmune diseases with lessened side reactions.

  本发明的螺环化合物由以下通式表示： 其中 A、R2、R3、R4、R5、R6 和 n 如说明书中所定义，具有 AP-1 活性抑制作用，并且基于 AP-1 抑制作用，可抑制多种基因的表达，可用作治疗和预防自身免疫性疾病的药物，且副作用较小。